Regeneron Pharmaceuticals, Inc. (REGN) on Monday said that it has entered into a strategic in-licensing agreement with China’s Hansoh Pharmaceuticals Group Company to acquire exclusive clinical ...

Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS ...

Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

at Regeneron, explained in the Hansoh deal release. “This is an exciting development in our obesity work at Regeneron, which also includes the muscle-sparing phase 2 COURAGE study investigating ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline ...

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies aim to reduce.

The deal, announced Monday ... trial in China and a Phase 2b diabetes study. Regeneron will make an $80 million upfront payment to Hansoh, with potential future payments totaling up to $1.93 ...

Regeneron will pay Hansoh $80m upfront ... Regeneron is expanding its clinical-stage obesity portfolio. The deal is subject to standard closing conditions, including clearances from regulatory ...

The deal, announced Monday ... Ongoing studies include a Phase 3 obesity trial in China and a Phase 2b diabetes study. Regeneron will make an $80 million upfront payment to Hansoh, with potential ...